DR.NOAH BIOTECH Achieves Milestone in ALS Treatment Approval
DR.NOAH BIOTECH, recognized for its innovative AI-driven solutions, has recently reached a significant milestone in its drug development efforts. The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Phase 1 clinical trials of a new drug combination, NDC-011, specifically designed to target Amyotrophic Lateral Sclerosis (ALS).
Overview of the Phase 1 Clinical Trial
The upcoming Phase 1 clinical trial will be conducted in the U.S. and will include 24 healthy adult participants. This trial aims to evaluate the bioavailability, safety, and tolerability of the individual components of NDC-011, which consists of a two-drug combination. It will assess the effects of single doses of each drug as well as the combination itself. The trial is expected to begin in the first half of 2025, followed by a Phase 2 trial anticipated to start in 2026.
A Distinctive Drug Combination for ALS
NDC-011 is notable as a product of DR.NOAH's proprietary AI drug development platform, known as 'ARK.' This formulation combines multiple therapeutic actions aimed at benefiting ALS patients, including anti-inflammatory properties, neuroprotection, promotion of neuronal differentiation, and muscle cell protection.
Preclinical Achievements and Future Outlook
The approval of NDC-011 has been supported by extensive research. Using the ARK platform, DR.NOAH carefully analyzed data from ALS patients and examined over 1.6 million drug combinations to pinpoint potential candidate drugs. This thorough selection process led to the identification of NDC-011, which demonstrated the most promising results in preclinical trials.
Preclinical studies have highlighted NDC-011's potential to not only slow down motor function decline but also extend survival in ALS models, with results published in the respected journal 'Neurotherapeutics.' This comprehensive study has been well-received within the ALS community, fostering hopes for improved outcomes for patients grappling with this challenging condition.
Commitment to Global Market Readiness
From the beginning, the development of NDC-011 has been aimed at international markets. To achieve this, rigorous formulation, preparation, and quality control processes were carried out at Patheon's advanced cGMP facility, a well-regarded contract development and manufacturing organization based in the U.S.
The Urgent Need for New ALS Treatments
A representative from DR.NOAH stressed the critical need for effective ALS treatments, pointing out that while some medications are available, their effectiveness often falls short of patient expectations. The launch of NDC-011 is seen as a crucial step towards mitigating disease progression and improving the quality of life for those living with ALS.
Additionally, DR.NOAH emphasizes its unique position as a company that not only provides AI technology solutions but also manages the entire drug development process—from initial discovery to clinical development.
Focus on Rare Diseases and Expanding Pipeline
DR.NOAH BIOTECH has consistently focused on developing treatments for neurological and muscular diseases. Since the introduction of the ARK platform in 2017, the company has been actively working on its own medications. The ARK system integrates various databases and AI technologies to facilitate precise predictions and optimal drug combinations for complex diseases. Currently, DR.NOAH is advancing eight different combination drug pipelines, showcasing its innovative approach.
A notable achievement is NDC-002 for stroke recovery, which successfully completed Phase 1 trials in Korea. This trial marked a significant milestone as it was the first time an AI-driven company in Korea led Phase 1 clinical trials for its own drug. Building on this success, DR.NOAH is also developing NDC-026, a treatment for Duchenne muscular dystrophy (DMD), which has received designations for rare pediatric diseases and orphan drugs from the FDA. The team aims to submit an IND application in 2025.
Looking Ahead with Hope
The start of clinical trials for NDC-011 marks a groundbreaking effort—a first for an AI-discovered combination drug specifically targeting ALS treatment. Dr. Ji-hyun Lee, CEO of DR.NOAH, expressed the company's commitment to continue developing medications for rare diseases. She reaffirmed her dedication to leveraging the AI-driven combination drug development strategy to bring hope to patients facing rare diseases worldwide.
Frequently Asked Questions
What is DR.NOAH BIOTECH’s recent achievement?
DR.NOAH BIOTECH has received FDA approval for Phase 1 clinical trials for its ALS treatment, NDC-011.
What is NDC-011?
NDC-011 is an innovative drug combination developed through AI technology aimed at treating Amyotrophic Lateral Sclerosis (ALS).
When will the Phase 1 clinical trial for NDC-011 begin?
The Phase 1 clinical trial is scheduled to start in the first half of 2025.
What are the expected outcomes of NDC-011?
NDC-011 aims to improve the quality of life for ALS patients by delaying disease progression and prolonging survival.
How does DR.NOAH BIOTECH utilize AI in drug development?
DR.NOAH employs its AI platform 'ARK' to analyze extensive patient data and identify optimal drug combinations tailored for various diseases.
